Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 10:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 332 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: insulin pre-treatment Clear all
Completed Not applicable Interventional Results available

Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver

NCT01986231
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Glucagon
Drug
Lead sponsor
Legacy Health System
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Oct 9, 2026, 10:46 PM EDT
Terminated Phase 4 Interventional Results available

Early Basal Insulin Administration in Adult Diabetic Ketoacidosis Management

NCT04567225
View directory record Official record
Conditions
Diabetic Ketoacidosis, Type 1 Diabetes, Type 2 Diabetes
Interventions
Early Glargine, Late Glargine, IV insulin infusion, IV fluid and electrolytes replacement
Drug · Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Effectiveness of Intraperitoneal Insulin Administration to Subcutaneous Insulin Administration

NCT00211536
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Medtronic MiniMed Implantable Pump Human Recombinant Insulin, Medtronic MiniMed Implantable Pump System, Aventis HOE21PH U400
Drug · Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
5
States / cities
Santa Barbara, California • Aurora, Colorado • North Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2011 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Insulin Degludec Titration Using Mobile Insulin Dosing System

NCT03091712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Glooko Mobile Insulin Dosing System(MIDS)
Device
Lead sponsor
Glooko
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

The Pediatric Artificial Pancreas (PEDAP) Trial of Control-IQ Technology in Young Children in Type 1 Diabetes

NCT04796779
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Tandem t:slim X2 with Control-IQ Technology Pro, Standard Care (SC), Tandem t:slim X2 with Control-IQ Technology V1.5
Device
Lead sponsor
Marc Breton
Other
Eligibility
24 Months to 71 Months
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Stanford, California • Aurora, Colorado • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2023 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Dopamine and Insulin Resistance

NCT00802204
View directory record Official record
Conditions
Obesity
Interventions
PET scan, Oral glucose tolerance test, MRI, Psychological scales to assess attitudes and behaviors related to eating and quality of life, Caloric Restriction
Radiation · Procedure · Behavioral + 1 more
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Improvement of Insulin Resistance After Bariatric Surgery

NCT03853590
View directory record Official record
Conditions
Obesity, Bariatric Surgery Candidate, Insulin Tolerance
Interventions
Roux-en-Y gastric bypass, Laparoscopic adjustable gastric banding
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional Results available

A Trial Comparing Continuous Glucose Monitoring With and Without Routine Blood Glucose Monitoring in Adults With Type 1 Diabetes

NCT02258373
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
CGM+BGM, CGM Only
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
226 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Beverly Hills, California • San Diego, California • Denver, Colorado + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Post-meal Insulin Dosing With Adjuvant Pre-meal Pramlintide in Children With Type 1 Diabetes Mellitus

NCT00442767
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Insulin, Pramlintide + Insulin
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
12 Years to 21 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jul 10, 2018 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Insulin Glargine at Bedtime or in AM Versus NPH

NCT00686712
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
1- Insulin glargine QHS, 2 - Insulin glargine QAM, 3 - NPH insulin QHS
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 75 Years
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 9, 2026, 10:46 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Soliqua Versus Lantus in Ethnically/Racially Diverse Patients With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Agents

NCT03434119
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/Lixisenatide, Insulin glargine (HOE901), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
241 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
85
States / cities
Montgomery, Alabama • Little Rock, Arkansas • Anaheim, California + 63 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2022 · Synced Oct 9, 2026, 10:46 PM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients

NCT02496780
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
novolog insulin, levemir insulin, placebo
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
10 Years to 25 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
2
States / cities
Minneapolis, Minnesota • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2011 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Treating the Endothelium to Restore Insulin Sensitivity

NCT00402194
View directory record Official record
Conditions
Obesity, Insulin Resistance, Impaired Glucose Tolerance, Pre-diabetes
Interventions
Losartan
Drug
Lead sponsor
Indiana University
Other
Eligibility
20 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 24, 2013 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 2 Interventional

Comparison of Hepatic Directed Vesicle (HDV)-Insulin Lispro Versus Insulin Lispro to Further Improve Glycemic Control

NCT03096392
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
HDV insulin lispro 100 UNT/ML, Insulin Lispro 100 UNT/ML
Drug
Lead sponsor
Diasome Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
5
States / cities
Aurora, Colorado • Miami, Florida • Morehead City, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 9, 2026, 10:46 PM EDT
Terminated Not applicable Interventional

Control:Diabetes Pilot Study I

NCT04158921
View directory record Official record
Conditions
Insulin Treated Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 1
Interventions
Control:Diabetes mobile app
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Study of Brain Function in Women With Insulin Resistant Polycystic Ovary Syndrome

NCT00670800
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Metformin
Drug
Lead sponsor
University of Michigan
Other
Eligibility
21 Years to 40 Years · Female only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 9, 2026, 10:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Fat Metabolism in Pregnancy and Neonatal Heart Function in Diabetes

NCT01346527
View directory record Official record
Conditions
Type 2 Diabetes, Pregnancy
Interventions
Not listed
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
79 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Randomized, Double Blind, 2 Way Crossover Study of CSII With, Versus Without, Pretreatment With Human Hyaluronidase

NCT01526733
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Sham Injection, Recombinant human hyaluronidase PH20, Insulin aspart, Insulin lispro
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Feb 26, 2019 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Insulin Glargine Versus Sitagliptin in Insulin-naive Patients

NCT00751114
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Sitagliptin, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
35 Years to 70 Years
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 9, 2026, 10:46 PM EDT
Completed No phase listed Observational

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Canagliflozin, Empagliflozin, Dapagliflozin, Dipeptidyl Peptidase-4 Inhibitor (DPP-4), Glucagon-Like Peptide-1 Agonist (GLP-1), Thiazolidinedione (TZD), Sulfonylureas, Insulin
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
25,358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Trevose, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Not applicable Interventional

Dietary Interventions in Prediabetes

NCT01729078
View directory record Official record
Conditions
Impaired Fasting Glucose, Pre Diabetes, Liver Fat
Interventions
Dietary intervention
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years to 80 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2015 · Synced Oct 9, 2026, 10:46 PM EDT
Completed Phase 3 Interventional

Efficacy of Islet After Kidney Transplantation

NCT00468117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Islet transplantation, Antithymocyte Globulin, Daclizumab or Basiliximab, Etanercept, Allogenic human purified pancreatic islets
Procedure · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 68 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
9
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2017 · Synced Oct 9, 2026, 10:46 PM EDT